Beijing Biostar Pharmaceuticals Co., Ltd. (BIOSTAR) announced that its external auditor anticipates issuing a qualified opinion on the consolidated financial statements for the year ended 31 December 2025.
The board is currently engaging with the auditor to resolve the matters leading to the expected qualification. Detailed information will be provided in the forthcoming FY2025 annual results release.
The company advised shareholders and potential investors to exercise caution when trading its shares.